The Difference Between Cystatin C– and Creatinine-Based Estimated GFR in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF

医学 危险系数 射血分数 胱抑素C 肾功能 内科学 心力衰竭 肌酐 比例危险模型 心脏病学 混淆 置信区间
作者
Alberto Pinsino,Matthew R. Carey,Syed Husain,Sumit Mohan,Jai Radhakrishnan,Douglas L. Jennings,Austin Nguonly,Annamaria Ladanyi,Lorenzo Braghieri,Koji Takeda,Robert T. FAILLACE,GABRIEL T. SAYER,Nir Y. Uriel,PAOLO C. COLOMBO,melana yuzefpolskaya
出处
期刊:American Journal of Kidney Diseases [Elsevier BV]
卷期号:82 (5): 521-533 被引量:33
标识
DOI:10.1053/j.ajkd.2023.03.005
摘要

Rationale & Objective The clinical implications of the discrepancy between cystatin C (cysC)– and serum creatinine (Scr)–estimated glomerular filtration rate (eGFR) in patients with heart failure (HF) and reduced ejection fraction (HFrEF) are unknown. Study Design Post-hoc analysis of randomized trial data. Setting & Participants 1,970 patients with HFrEF enrolled in PARADIGM-HF with available baseline cysC and Scr measurements. Exposure Intraindividual differences between eGFR based on cysC (eGFRcysC) and Scr (eGFRScr; eGFRdiffcysC-Scr). Outcomes Clinical outcomes included the PARADIGM-HF primary end point (composite of cardiovascular [CV] mortality or HF hospitalization), CV mortality, all-cause mortality, and worsening kidney function. We also examined poor health-related quality of life (HRQoL), frailty, and worsening HF (WHF), defined as HF hospitalization, emergency department visit, or outpatient intensification of therapy between baseline and 8-month follow-up. Analytical Approach Fine-Gray subdistribution hazard models and Cox proportional hazards models were used to regress clinical outcomes on baseline eGFRdiffcysC-Scr. Logistic regression was used to investigate the association of baseline eGFRdiffcysC-Scr with poor HRQoL and frailty. Linear regression models were used to assess the association of WHF with eGFRcysC, eGFRScr, and eGFRdiffcysC-Scr at 8-month follow-up. Results Baseline eGFRdiffcysC-Scr was higher than +10 and lower than −10 mL/min/1.73 m2 in 13.0% and 35.7% of patients, respectively. More negative values of eGFRdiffcysC-Scr were associated with worse outcomes ([sub]hazard ratio per standard deviation: PARADIGM-HF primary end point, 1.18; P = 0.008; CV mortality, 1.34; P = 0.001; all-cause mortality, 1.39; P < 0.001; worsening kidney function, 1.31; P = 0.05). For a 1–standard-deviation decrease in eGFRdiffcysC-Scr, the prevalences of poor HRQoL and frailty increased by 29% and 17%, respectively (P ≤ 0.008). WHF was associated with a more pronounced decrease in eGFRcysC than in eGFRScr, resulting in a change in 8-month eGFRdiffcysC-Scr of −4.67 mL/min/1.73 m2 (P < 0.001). Limitations Lack of gold-standard assessment of kidney function. Conclusions In patients with HFrEF, discrepancies between eGFRcysC and eGFRScr are common and are associated with clinical outcomes, HRQoL, and frailty. The decline in kidney function associated with WHF is more marked when assessed with eGFRcysC than with eGFRScr. Plain-Language Summary Kidney function assessment traditionally relies on serum creatinine (Scr) to establish an estimated glomerular filtration rate (eGFR). However, this has been challenged with the introduction of an alternative marker, cystatin C (cysC). Muscle mass and nutritional status have differential effects on eGFR based on cysC (eGFRcysC) and Scr (eGFRScr). Among ambulatory patients with heart failure enrolled in PARADIGM-HF, we investigated the clinical significance of the difference between eGFRcysC and eGFRScr. More negative values (ie, eGFRScr > eGFRcysC) were associated with worse clinical outcomes (including mortality), poor quality of life, and frailty. In patients with progressive heart failure, which is characterized by muscle loss and poor nutritional status, the decline in kidney function was more pronounced when eGFR was estimated using cysC rather than Scr. The clinical implications of the discrepancy between cystatin C (cysC)– and serum creatinine (Scr)–estimated glomerular filtration rate (eGFR) in patients with heart failure (HF) and reduced ejection fraction (HFrEF) are unknown. Post-hoc analysis of randomized trial data. 1,970 patients with HFrEF enrolled in PARADIGM-HF with available baseline cysC and Scr measurements. Intraindividual differences between eGFR based on cysC (eGFRcysC) and Scr (eGFRScr; eGFRdiffcysC-Scr). Clinical outcomes included the PARADIGM-HF primary end point (composite of cardiovascular [CV] mortality or HF hospitalization), CV mortality, all-cause mortality, and worsening kidney function. We also examined poor health-related quality of life (HRQoL), frailty, and worsening HF (WHF), defined as HF hospitalization, emergency department visit, or outpatient intensification of therapy between baseline and 8-month follow-up. Fine-Gray subdistribution hazard models and Cox proportional hazards models were used to regress clinical outcomes on baseline eGFRdiffcysC-Scr. Logistic regression was used to investigate the association of baseline eGFRdiffcysC-Scr with poor HRQoL and frailty. Linear regression models were used to assess the association of WHF with eGFRcysC, eGFRScr, and eGFRdiffcysC-Scr at 8-month follow-up. Baseline eGFRdiffcysC-Scr was higher than +10 and lower than −10 mL/min/1.73 m2 in 13.0% and 35.7% of patients, respectively. More negative values of eGFRdiffcysC-Scr were associated with worse outcomes ([sub]hazard ratio per standard deviation: PARADIGM-HF primary end point, 1.18; P = 0.008; CV mortality, 1.34; P = 0.001; all-cause mortality, 1.39; P < 0.001; worsening kidney function, 1.31; P = 0.05). For a 1–standard-deviation decrease in eGFRdiffcysC-Scr, the prevalences of poor HRQoL and frailty increased by 29% and 17%, respectively (P ≤ 0.008). WHF was associated with a more pronounced decrease in eGFRcysC than in eGFRScr, resulting in a change in 8-month eGFRdiffcysC-Scr of −4.67 mL/min/1.73 m2 (P < 0.001). Lack of gold-standard assessment of kidney function. In patients with HFrEF, discrepancies between eGFRcysC and eGFRScr are common and are associated with clinical outcomes, HRQoL, and frailty. The decline in kidney function associated with WHF is more marked when assessed with eGFRcysC than with eGFRScr.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王哈佛发布了新的文献求助10
1秒前
肘子完成签到,获得积分10
1秒前
zzz发布了新的文献求助10
2秒前
英俊的铭的应助被billc73采纳,获得10
2秒前
Sigar完成签到 ,获得积分10
2秒前
2秒前
3秒前
ZD发布了新的文献求助10
3秒前
冷静之云发布了新的文献求助10
3秒前
3秒前
Owen的应助被qky采纳,获得10
4秒前
Sia发布了新的文献求助30
4秒前
wanci的应助被波波子采纳,获得30
5秒前
5秒前
5秒前
6秒前
xl发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
7秒前
霸气的思柔完成签到,获得积分10
9秒前
Nihai完成签到 ,获得积分10
10秒前
10秒前
情怀的应助被18756828852采纳,获得10
11秒前
Echo完成签到 ,获得积分10
11秒前
11秒前
SUN发布了新的文献求助10
11秒前
12秒前
GG酱发布了新的文献求助10
12秒前
ZP完成签到,获得积分20
12秒前
等待广缘发布了新的文献求助10
12秒前
佘炭炭发布了新的文献求助10
12秒前
13秒前
14秒前
fxl666完成签到,获得积分10
14秒前
ZP发布了新的文献求助10
15秒前
15秒前
Kyra发布了新的文献求助10
16秒前
lh完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192841
求助须知:如何正确求助?哪些是违规求助? 9579236
关于积分的说明 21864289
捐赠科研通 7792410
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483927